NKG2A trapping in the endoplasmic reticulum/Golgi by smartly designed protein expression blockers (PEBLs) (183) or the treatment with anti-NKG2A blocking antibodies, broadens the oncolytic activity of NK cells against hematological tumors such as AML, CLL or lymphomas (184). Here, KLRC1 is linked to lymphoma.